| Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 21918510 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Paraoxonase-1 (PON1) Q192R polymorphism was recently suggested to determine per se clopidogrel response on major cardiovascular events (MACEs). We assessed the impact of PON1, CYP2C19, and ABCB1 polymorphisms on MACE in clopidogrel-treated acute myocardial infarction (AMI) patients (N = 2,210), including those undergoing percutaneous coronary intervention (PCI) (n = 1,538). PON1 polymorphism was not associated with increased risk of in-hospital death and MACEs at 1 year (adjusted hazard ratio (HR) 1.03, 95% confidence interval (CI) 0.66-1.61 and adjusted HR 0.77, 95% CI 0.42-1.41 for QQ versus RR in all and PCI patients, respectively). The presence of two CYP2C19 loss-of-function (LOF) alleles was associated with the risk of in-hospital death and MACEs at 1 year in the overall population (adjusted odds ratio (OR) 3.67, 95% CI 1.05-12.80 and adjusted HR 1.96, 95% CI 1.08-3.54) and in PCI patients (adjusted OR 6.87, 95% CI 2.52-18.72 and adjusted HR 3.06, 95% CI 1.47-6.41). Unlike CYP2C19 polymorphism, PON1 (Q192R) polymorphism is not a major pharmacogenetic contributor of clinical response to clopidogrel in AMI patients. |
| | |
Authors:
|
T Simon; P G Steg; L Becquemont; C Verstuyft; S Kotti; F Schiele; E Ferrari; E Drouet; G Grollier; N Danchin |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2011-09-14 |
Journal Detail:
|
Title: Clinical pharmacology and therapeutics Volume: 90 ISSN: 1532-6535 ISO Abbreviation: Clin. Pharmacol. Ther. Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-21 Completed Date: 2011-11-23 Revised Date: 2011-12-23 |
Medline Journal Info:
|
Nlm Unique ID: 0372741 Medline TA: Clin Pharmacol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 561-7 Citation Subset: AIM; IM |
Affiliation:
|
Assistance Publique-Hôpitaux de Paris (APHP), Hôpital St. Antoine, URC-EST, Paris, France. tabassome.simon@sat.aphp.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Aryldialkylphosphatase / genetics* Female Follow-Up Studies Genotype Hospital Mortality / trends Humans Male Middle Aged Myocardial Infarction / drug therapy*, genetics*, mortality Polymorphism, Genetic / genetics* Prospective Studies Registries Ticlopidine / analogs & derivatives*, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
55142-85-3/Ticlopidine; 90055-48-4/clopidogrel; EC 3.1.8.1/Aryldialkylphosphatase; EC 3.1.8.1/PON1 protein, human |
| Comments/Corrections | |
Comment In:
|
Clin Pharmacol Ther. 2011 Dec;90(6):771-4
[PMID:
22089342
]
Clin Pharmacol Ther. 2011 Dec;90(6):774-6 [PMID: 22089343 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacogenomics: application to the management of cardiovascular disease.
Next Document: Synthetic chromosome arms function in yeast and generate phenotypic diversity by design.